Challenges and opportunities for next-generation sequencing in companion diagnostics

The rapid decline in sequencing costs has allowed next-generation sequencing (NGS) assays, previously ubiquitous only in research laboratories, to begin making inroads into molecular diagnostics. Genotypic assays – DNA sequencing – include whole genome sequencing, whole exome sequencing, focused assays that target only a handful of genes. Phenotypic assays comprise a broader spectrum of options and can query a variety of epigenetic modifications of DNA (such as ChIP-seq, bisulfite sequencing, DNase-I hypersensitivity site-sequencing, Formaldehyde-Assisted Isolation of Regulatory Elements-sequencing, etc.) that regulate gene expression-related processes or gene expression (RNA-sequencing) itself. To date, the US FDA has only cleared 12 DNA-based companion diagnostic tests, all in cancer. Although challenges exist for NGS in companion diagnostics, the wide-ranging capabilities of NGS offer extraordinary opportunities for the development and implementation of NGS-based companion diagnostics to probe oncogenes, tumor suppressor genes and cancer-enabling genes.

[1]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[2]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[3]  V. Rotter,et al.  Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[4]  S. Amladi,et al.  Online Mendelian Inheritance in Man 'OMIM'. , 2003, Indian journal of dermatology, venereology and leprology.

[5]  Terence P. Speed,et al.  Comparing somatic mutation-callers: beyond Venn diagrams , 2013, BMC Bioinformatics.

[6]  Gary D Bader,et al.  Computational approaches to identify functional genetic variants in cancer genomes , 2013, Nature Methods.

[7]  A. Marchetti,et al.  Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing , 2012, Clinical Cancer Research.

[8]  Heng Zhao,et al.  Identification of candidate genes for lung cancer somatic mutation test kits , 2013, Genetics and molecular biology.

[9]  N. Rosenfeld,et al.  Circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[10]  Rashmi Kanagal-Shamanna,et al.  Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.

[11]  Erica A. Bowton,et al.  Stakeholder engagement: a key component of integrating genomic information into electronic health records , 2013, Genetics in Medicine.

[12]  Doris Berger,et al.  International Cancer Genome Consortium , 2013, Im Focus Onkologie.

[13]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[14]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[15]  Jing Zhang,et al.  Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing , 2014, Briefings Bioinform..

[16]  L. Ellis,et al.  Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology , 2009, Clinical Cancer Research.

[17]  J. Andrews,et al.  Comparison of Targeted Next‐Generation Sequencing (NGS) and Real‐Time PCR in the Detection of EGFR, KRAS, and BRAF Mutations on Formalin‐Fixed, Paraffin‐Embedded Tumor Material of Non‐Small Cell Lung Carcinoma—Superiority of NGS , 2013, Genes, chromosomes & cancer.

[18]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[19]  Toshihiro Tanaka.  The International HapMap Project , 2003, Nature.

[20]  Peter Saffrey,et al.  Rapid Whole-Genome Sequencing for Genetic Disease Diagnosis in Neonatal Intensive Care Units , 2012, Science Translational Medicine.

[21]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[22]  E. Duncavage,et al.  Targeted next‐generation sequencing using fine‐needle aspirates from adenocarcinomas of the lung , 2014, Cancer cytopathology.

[23]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Matthew S. Lebo,et al.  A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record , 2013, Genetics in Medicine.

[25]  Chao Xie,et al.  CNV-seq, a new method to detect copy number variation using high-throughput sequencing , 2009, BMC Bioinformatics.

[26]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[27]  X. Xie,et al.  Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients , 2013, Proceedings of the National Academy of Sciences.

[28]  Shibing Deng,et al.  Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. , 2013, Genomics.

[29]  M. Berger,et al.  Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing , 2014, Molecular Oncology.

[30]  S. Elledge,et al.  Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells , 2007, Cell.

[31]  M. Metzker.  Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[32]  R. Wilson,et al.  BreakDancer: An algorithm for high resolution mapping of genomic structural variation , 2009, Nature Methods.

[33]  S. Gabriel,et al.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.

[34]  R. S. Huang,et al.  肺癌的下一代测序技术 , 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[35]  Jason Li,et al.  Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. , 2013, Clinical chemistry.

[36]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[37]  Gary D Bader,et al.  Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers , 2013 .

[38]  Abel N. Kho,et al.  Practical challenges in integrating genomic data into the electronic health record , 2013, Genetics in Medicine.

[39]  Thomas Helleday,et al.  The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.

[40]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[41]  Simon Tavaré,et al.  CNAseg - a novel framework for identification of copy number changes in cancer from second-generation sequencing data , 2010, Bioinform..

[42]  E. Oikonomou,et al.  Tumor Heterogeneity Revealed by KRAS, BRAF, and PIK3CA Pyrosequencing: KRAS and PIK3CA Intratumor Mutation Profile Differences and Their Therapeutic Implications , 2014, Human mutation.

[43]  X. Estivill,et al.  PeSV-Fisher: Identification of Somatic and Non-Somatic Structural Variants Using Next Generation Sequencing Data , 2013, PloS one.

[44]  Eugene J. Schweitzer,et al.  Reconciliation of the cloud computing model with US federal electronic health record regulations , 2012, J. Am. Medical Informatics Assoc..

[45]  Liliana Florea,et al.  Transcriptomic landscape of breast cancers through mRNA sequencing , 2012, Scientific Reports.

[46]  Yi-Song Wang,et al.  From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Elisabeth Brambilla,et al.  Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  K. Sirotkin,et al.  dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. , 1999, Genome research.

[49]  P. Liberski,et al.  Limited importance of the dominant-negative effect of TP53 missense mutations , 2011, BMC Cancer.

[50]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[51]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[52]  Jun Liu,et al.  Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  P. Fortina,et al.  Circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[54]  Emilie Lalonde,et al.  Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient , 2013, BMC Cancer.

[55]  Scott D. Kahn.  On the Future of Genomic Data , 2011, Science.

[56]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[57]  Iftikhar J. Kullo,et al.  Ethical, legal, and social implications of incorporating genomic information into electronic health records , 2013, Genetics in Medicine.

[58]  S. Grant,et al.  Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. , 2013, Leukemia research reports.

[59]  D. Berry.  Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.

[60]  Aviv Regev,et al.  Whole exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer , 2014, Nature Biotechnology.

[61]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[62]  H. Kantarjian,et al.  Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. , 2011, Blood.

[63]  L. Trusolino,et al.  Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. , 2014, Biochimica et biophysica acta.

[64]  Peiyong Jiang,et al.  Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing , 2013, Proceedings of the National Academy of Sciences.

[65]  Timothy B. Stockwell,et al.  Evaluation of next generation sequencing platforms for population targeted sequencing studies , 2009, Genome Biology.

[66]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[67]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[68]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.